IDEX Q4 sales -3%, adjusted EPS $1.83 (-9% YoY); FY2024 adjusted EPS guidance $8.15-$8.45

IDEX CORP /DE/

2023-FY EPS reported $7.85 revenue$3,273,900,000

Q4 sales $789M (-3%, -6% organic); GAAP EPS $1.43 (-16%), adjusted EPS $1.83 (-9%).
Full-year record sales $3.3B, record adjusted EPS $8.22 (+1%), record free cash flow $627M.
HST segment sales -11% YoY (-19% organic); adjusted EBITDA margin 25.8% (-450bps) on weak Life Sciences.
Acquired STC Material Solutions for $202M in Dec 2023; divested Novotema with $9.1M loss.
FY2024 outlook: organic sales growth 0-2%, GAAP EPS $7.15-$7.45, adjusted EPS $8.15-$8.45.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEX CORP /DE/ reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 6, 2024, IDEX Corporation (the "Company") issued a press release announcing financial results for the period ended December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEX CORP /DE/ reported financial results for the quarter ended December 31, 2023.

Period: the quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 6, 2024, IDEX Corporation (the "Company") issued a press release announcing financial results for the period ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEX CORP /DE/ filing history →

Source: SEC EDGAR

accession 0000832101-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.